Vista Pharmaceuticals Ltd
Vista Pharmaceuticals Ltd (VISTAPH) last reported results for the quarter ended Jun 2026, with sales of ₹-0 crore and net profit of ₹-0.99 crore. The stock last traded at ₹6.44, a market capitalisation of ₹39.6 crore. Over the past 52 weeks the stock has ranged between ₹5.32 and ₹10.5. Figures are as of 6 Oct 2026 and are not real time.
Vista Pharmaceuticals Ltd share price and key metrics
- Current price
- ₹6.44
- Market cap
- ₹39.6 cr
- Book value
- ₹5.92
- ROE
- -29.5%
- ROCE
- -30.3%
- Dividend yield
- 0.00%
- 52w high / low
- 10.5/5.32
Metrics as of 6 Oct 2026. Not real time.
Track Vista Pharmaceuticals Ltd
Cruxal reads every Vista Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Vista Pharmaceuticals Ltd growth and returns
- 10 Years
- -10%
- 5 Years
- 34%
- 3 Years
- 75%
- TTM
- -60%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- -132%
- 10 Years
- -12%
- 5 Years
- -9%
- 3 Years
- -30%
- 1 Year
- -39%
- 10 Years
- -9%
- 5 Years
- -14%
- 3 Years
- -17%
- Last Year
- -29%
Vista Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹-0 cr, down 100.0% from ₹1.52 cr a year earlier. Net profit was ₹-0.99 cr, up 23.3% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 2.49 | 2.56 | 3.23 | 1.52 | 1.46 | 2.42 | -0 | -0 |
| Expenses | 3.32 | 4.08 | 4.14 | 2.63 | 4.89 | 5.42 | 7.06 | 0.84 |
| Operating profit | -0.83 | -1.52 | -0.91 | -1.11 | -3.43 | -3 | -7.06 | -0.84 |
| OPM % | -33.33% | -59.38% | -28.17% | -73.03% | -234.93% | -123.97% | — | — |
| Other income | 0.01 | 0.12 | 0.24 | -0 | 0.19 | 0.09 | 0.03 | 0.04 |
| Interest | 0.25 | 0.22 | 0.21 | 0.19 | 0.18 | 0.18 | 0.55 | 0.34 |
| Depreciation | 0.18 | 0.19 | 0.18 | 0.18 | 0.2 | 0.19 | 0.19 | 0.19 |
| Profit before tax | -1.25 | -1.81 | -1.06 | -1.48 | -3.62 | -3.28 | -7.77 | -1.33 |
| Tax % | -22.40% | -26.52% | 40.57% | -12.84% | -28.45% | -29.27% | -24.58% | -25.56% |
| Net profit | -0.97 | -1.32 | -1.5 | -1.29 | -2.59 | -2.32 | -5.86 | -0.99 |
| EPS (₹) | -0.26 | -0.36 | -0.41 | -0.21 | -0.42 | -0.38 | -0.95 | -0.16 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Vista Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 24 | 29 | 31 | 23 | 1 | 0 | 1 | 10 | 10 | 5 | 4 |
| Operating profit | 3 | 5 | 1 | -5 | -2 | -1 | -4 | -3 | -4 | -15 | -14 |
| OPM % | 13% | 18% | 4.0% | -21% | -136% | -326% | -432% | -33% | -41% | -271% | -369% |
| Net profit | 1 | 2 | 1 | -4 | -2 | -1 | -6 | -5 | -5 | -12 | -12 |
| EPS (₹) | 0.47 | 0.75 | 0.31 | -1.21 | -0.55 | -0.24 | -1.54 | -1.23 | -1.26 | -1.96 | -1.91 |
TTM is the trailing twelve months to the most recent quarter.
Vista Pharmaceuticals Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 5 | 6 | 6 | 6 | 7 | 7 | 8 | 9 | 12 | 12 |
| Reserves | 11 | 26 | 30 | 24 | 25 | 28 | 29 | 31 | 33 | 24 |
| Borrowings | 11 | 11 | 11 | 15 | 11 | 13 | 10 | 8 | 7 | 10 |
| Other liabilities | 14 | 10 | 6 | 6 | 9 | 8 | 9 | 10 | 7 | 9 |
| Total liabilities | 42 | 53 | 53 | 51 | 53 | 56 | 56 | 58 | 60 | 55 |
| Fixed assets | 13 | 18 | 21 | 21 | 20 | 19 | 20 | 19 | 19 | 18 |
| CWIP | 2 | 7 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 11 |
| Investments | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 26 | 28 | 24 | 22 | 24 | 27 | 27 | 29 | 31 | 26 |
| Total assets | 42 | 53 | 53 | 51 | 53 | 56 | 56 | 58 | 60 | 55 |
As reported by the company. Total assets equal total liabilities by construction.
Vista Pharmaceuticals Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 3 | -5 | 3 | 1 | -7 | -1 | -2 | -5 | -7 | -4 |
| Cash from investing | -4 | -11 | -6 | -2 | -0 | -0 | -1 | -1 | -0 | -1 |
| Cash from financing | 6 | 11 | 1 | 0 | 7 | 1 | 3 | 6 | 8 | 5 |
| Net cash flow | 5 | -4 | -1 | -1 | -0 | -0 | 0 | -0 | 1 | -1 |
| Free cash flow | -1 | -15 | -2 | -1 | -7 | -1 | -3 | -6 | -7 | -5 |
| CFO / operating profit | 84% | -86% | 299% | -17% | 390% | 78% | 64% | 149% | 163% | 30% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Vista Pharmaceuticals Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 9% | 12% | 6% | -5% | -5% | -4% | -10% | -8% | -9% | -30% |
| Debtor days | 136 | 137 | 98 | 165 | 624 | 9,789 | 4,106 | 515 | 505 | 22 |
| Inventory days | 185 | 250 | 162 | 148 | 4,840 | 9,204 | 991 | 279 | 359 | 770 |
| Days payable | 293 | 209 | 76 | 79 | 2,555 | 5,297 | 1,007 | 304 | 244 | 443 |
| Cash conversion cycle | 27 | 178 | 184 | 234 | 2,909 | 13,696 | 4,089 | 490 | 620 | 349 |
| Working capital days | 12 | 137 | 137 | 81 | 1,681 | 10,154 | 3,460 | 318 | 440 | -95 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Vista Pharmaceuticals Ltd shareholding pattern
Promoters held 21.19% at Jun 2026, broadly unchanged since Jun 2025. DIIs 0.02%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 21.19% | 21.19% | 21.19% | 21.19% | 21.19% | 21.19% | 21.19% | 21.19% |
| DIIs | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% |
| Public | 78.79% | 78.79% | 78.78% | 78.78% | 78.78% | 78.78% | 78.80% | 78.80% |
| No. of shareholders | 13,913 | 14,086 | 14,158 | 14,061 | 14,012 | 14,080 | 14,154 | 14,154 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Vista Pharmaceuticals Ltd corporate filings
- Vista Pharmaceuticals Limited announces resignation of Company Secretary and Compliance OfficerCompany Updatelow impact
Cruxal's analysis: Vista Pharmaceuticals Limited has formally notified the exchange regarding the…
Read the full analysis - Vista Pharmaceuticals reports zero revenue and continued net losses for Q1 FY2027, citing severe liquidity constraints and NPA classificationResulthigh impact
Cruxal's analysis: Vista Pharmaceuticals Limited reported nil revenue from operations for the quarter ended…
Read the full analysis - Vista Pharmaceuticals Limited schedules Board Meeting for August 14, 2026, to approve Q1 FY27 financial resultsBoard Meetinglow impact
Cruxal's analysis: Vista Pharmaceuticals Limited has formally intimated the BSE regarding a Board Meeting…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.